Enzon Pharmaceuticals, Inc.'s HIF-1 Alpha Antagonist Shows Antitumor Activity

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) presented data from its pipeline programs at the 2008 EORTC-NCI-AACR (European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research) annual meeting in Geneva, Switzerland.
MORE ON THIS TOPIC